(CercleFinance.com) – Sanofi announced on Monday that new data on Dupixent have revealed a “homogeneous” long-term safety and efficacy profile in pediatric asthma.
These results, from the extension phase of a phase III trial, show that the effect of the drug, administered as maintenance treatment and in combination with other antiasthmatics, remained homogeneous for a period of up to two years in children aged 6 to 11 years with moderate to severe asthma with type 2 inflammatory signature.
These conclusions show in particular a low rate of severe asthma attacks, with an average of 0.118-0.124 attacks per year, against 2.16-2.56 attacks per year on inclusion in the pivotal trial.
The study also showed a sustained improvement in respiratory function in the range of 9.4-12.6 percentage points from baseline to week 52.
These results were presented today as part of a so-called ‘last minute’ session of the 2022 International Congress of the European Respiratory Society (ERS).